Definium Therapeutics
DFTX
104 hedge funds and large institutions have $11.1M invested in Definium Therapeutics in 2022 Q4 according to their latest regulatory filings, with 29 funds opening new positions, 19 increasing their positions, 24 reducing their positions, and 22 closing their positions.
322% more call options, than puts
Call options by funds: $9.46M | Put options by funds: $2.24M
32% more first-time investments, than exits
New positions opened: 29 | Existing positions closed: 22
3% more funds holding
Funds holding: 101 → 104 (+3)
5.89% less ownership
Funds ownership: 19.37% → 13.48% (-5.9%)
21% less repeat investments, than reductions
Existing positions increased: 19 | Existing positions reduced: 24
46% less capital invested
Capital invested by funds: $20.5M → $11.1M (-$9.39M)
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.61M |
| 2 |
BlackRock
New York
|
+$1.17M |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
+$782K |
| 4 |
Charles Schwab
San Francisco,
California
|
+$504K |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$460K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DCI
Data Collective IV
Palo Alto,
California
|
-$3.9M |
| 2 |
CH
CVI Holdings
Wilmington,
Delaware
|
-$2.28M |
| 3 |
MFG
Merit Financial Group
Alpharetta,
Georgia
|
-$1.5M |
| 4 |
Swiss National Bank
Zurich,
Switzerland
|
-$198K |
| 5 |
Group One Trading
Chicago,
Illinois
|
-$174K |
DFTX Hedge Fund Activity: Q4 2022 in Review
104 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in Definium Therapeutics (DFTX) for Q4 2022, worth a combined $11.1M — down 46% from $20.5M a quarter earlier.
Buyers outnumbered sellers: 29 funds opened new DFTX positions and 22 closed out — a net gain of 7 holders — while 19 added to existing stakes and 24 trimmed.
The largest buyer was Vanguard Group, adding an estimated $1.61M. The largest seller was Data Collective IV, cutting an estimated $3.9M.
- 104 institutional investors held Definium Therapeutics (DFTX) as of Q4 2022, up from 101 in Q3 2022.
- Funds reported $11.1M of Definium Therapeutics stock for Q4 2022, down 46% quarter-over-quarter.
- 29 funds opened new Definium Therapeutics positions in Q4 2022 and 22 closed out, a net change of +7 holders.
- The largest Definium Therapeutics buyer in Q4 2022 was Vanguard Group, an estimated $1.61M added.
- The largest Definium Therapeutics seller in Q4 2022 was Data Collective IV, an estimated $3.9M sold.
Based on aggregated 13F filings for Q4 2022.